2
|
Zhang L, Zhang Y, Zhu M, Pei L, Deng F, Chen J, Zhang S, Cong Z, Du W, Xiao X. An Integrative Pharmacology-Based Strategy to Uncover the Mechanism of Xiong-Pi-Fang in Treating Coronary Heart Disease with Depression. Front Pharmacol 2021; 12:590602. [PMID: 33867976 PMCID: PMC8048422 DOI: 10.3389/fphar.2021.590602] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2020] [Accepted: 02/11/2021] [Indexed: 12/24/2022] Open
Abstract
Objectives: This study aimed to explore the mechanism of Xiong-Pi-Fang (XPF) in the treatment of coronary heart disease (CHD) with depression by an integrative strategy combining serum pharmacochemistry, network pharmacology analysis, and experimental validation. Methods: An ultrahigh performance liquid chromatography-quadrupole-time-of-flight tandem mass spectrometry (UPLC-Q-TOF/MS) method was constructed to identify compounds in rat serum after oral administration of XPF, and a component-target network was established using Cytoscape, between the targets of XPF ingredients and CHD with depression. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed to deduce the mechanism of XPF in treating CHD with depression. Finally, in a chronic unpredictable mild stress (CUMS)-and isoproterenol (ISO)-induced rat model, TUNEL was used to detect the apoptosis index of the myocardium and hippocampus, ELISA and western blot were used to detect the predicted hub targets, namely AngII, 5-HT, cAMP, PKA, CREB, BDNF, Bcl-2, Bax, Cyt-c, and caspase-3. Results: We identified 51 compounds in rat serum after oral administration of XPF, which mainly included phenolic acids, saponins, and flavonoids. Network pharmacology analysis revealed that XPF may regulate targets, such as ACE2, HTR1A, HTR2A, AKT1, PKIA, CREB1, BDNF, BCL2, BAX, CASP3, cAMP signaling pathway, and cell apoptosis process in the treatment of CHD with depression. ELISA analysis showed that XPF decreased Ang-II content in the circulation and central nervous system, inhibited 5-HT levels in peripheral circulation, and increased 5-HT content in the central nervous system and cAMP content in the myocardia and hippocampus. Meanwhile, western blot analysis indicated that XPF could upregulate the expression levels of PKA, CREB, and BDNF both in the myocardia and hippocampus. TUNEL staining indicated that the apoptosis index of myocardial and hippocampal cells increased in CUMS-and ISO-induced CHD in rats under depression, and XPF could increase the expression of Bcl-2, inhibit the expression of Bax, Cyt-c, and caspase-3, and rectify the injury of the hippocampus and myocardium, which exerted antidepressant and antimyocardial ischemia effects. Conclusion: Our study proposed an integrated strategy, combining serum pharmacochemistry and network pharmacology to investigate the mechanisms of XPF in treating CHD with depression. The mechanism of XPF in treating CHD with depression may be related to the activation of the cAMP signaling pathway and the inhibition of the apoptosis.
Collapse
Affiliation(s)
- Lihong Zhang
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Yu Zhang
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Mingdan Zhu
- Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Limin Pei
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Fangjun Deng
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - JinHong Chen
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Shaoqiang Zhang
- Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Zidong Cong
- Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Wuxun Du
- Second Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Xuefeng Xiao
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| |
Collapse
|
3
|
Xi Y, Wu G, Ai T, Cheng N, Kalisnik JM, Sun J, Abbasi S, Yang D, Fan C, Yuan X, Wang S, Elayda M, Gregoric ID, Kantharia BK, Lin SF, Cheng J. Ionic Mechanisms Underlying the Effects of Vasoactive Intestinal Polypeptide on Canine Atrial Myocardium. Circ Arrhythm Electrophysiol 2013; 6:976-83. [DOI: 10.1161/circep.113.000518] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Yutao Xi
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Geru Wu
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Tomohiko Ai
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Nancy Cheng
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Jurij Matija Kalisnik
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Junping Sun
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Shahrzad Abbasi
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Donghui Yang
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Christopher Fan
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Xiaojing Yuan
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Suwei Wang
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - MacArthur Elayda
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Igor D. Gregoric
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Bharat K. Kantharia
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Shien-Fong Lin
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| | - Jie Cheng
- From the Texas Heart Institute/St. Luke’s Episcopal Hospital, Houston (Y.X., G.W., N.C., J.M.K., J.S., S.A., D.Y., C.F., S.W., M.E., J.C.); Krannert Institute of Cardiology, Indiana University, Indianapolis (T.A., S.-F.L.); Engineering Technology Department, University of Houston, TX (X.Y.); and Center for Advanced Heart Failure (I.D.G.) and Section of Cardiology (Y.X., B.K.K., J.C.), University of Texas Health Science Center at Houston
| |
Collapse
|